Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…
People with hereditary angioedema (HAE) are able to recognize early signs of swelling attacks and the need to get prompt on-demand treatment to manage them, new research highlights. Findings were presented by KalVista Pharmaceuticals in a series of posters at the recent U.S. Hereditary Angioedema Association (HAEA)…
BioCryst Pharmaceuticals is teaming up with Er-Kim Pharmaceuticals to commercialize Orladeyo (berotralstat) in Turkey. Orladeyo is an oral therapy, taken once a day, to prevent swelling attacks with hereditary angioedema (HAE). Er-Kim, based in Istanbul, partners with pharma companies to bring new therapies to markets around…
A woman still doesn’t have a definitive answer as to the underlying cause of her angioedema after more than a decade of recurrent facial swelling, underscoring the difficulties in diagnosing the condition. “This case report demonstrates the challenge of the differential diagnosis of angioedema without wheals,” the researchers wrote…
The U.S. Food and Drug Administration (FDA) has lifted its hold on clinical trials of deucrictibant for the on-demand treatment of hereditary angioedema (HAE). The therapy’s developer Pharvaris now expects to resume RAPIDe-2 (NCT05396105), a long-term extension study evaluating PHVS416, an immediate-release capsule formulation of deucrictibant,…
People with hereditary angioedema (HAE) tend to experience fewer emergency room visits and hospitalizations after starting treatment with Haegarda or Takhzyro (lanadelumab), a new analysis indicates. Despite the decreasing rates, some patients still experience health emergencies while on these therapies, which researchers said highlights the burden of…
On-demand treatment with the experimental oral therapy PHVS416 was found to quickly and effectively ease symptoms of swelling attacks for people with hereditary angioedema (HAE) in a Phase 2 clinical trial. PHVS416 worked within hours of dosing, providing “clinical meaningful” reductions in swelling symptoms, according to researchers. Pharvaris,…
Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary angioedema (HAE) in a Phase 1/2 trial have been free from swelling attacks. Three patients with high pretreatment attack rates, ranging from 4.4 to 16.8 each month, have gone without…
Get regular updates to your inbox.